- The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. [Journal Article]
- BIBrain Inj 2018 Dec 03; :1-2
- Clinical trial on the effects of amantadine on traumatic brain injury outcome. Is there more than meets the eye? [Journal Article]
- BIBrain Inj 2018 Dec 05; :1-2
- Effect of amantadine on vegetative state after traumatic brain injury: a functional magnetic resonance imaging study. [Journal Article]
- JIJ Int Med Res 2018 Dec 05; :300060518814127
- CONCLUSIONS: fMRI could be used to observe the effects of amantadine on brain function, and to aid the diagnosis and prognostic prediction in VS patients in terms of recovery and rehabilitation planning.
- Amantadine as adjuvant therapy in the treatment of moderate to severe OCD: a double blind randomized trial with placebo control. [Journal Article]
- PCPsychiatry Clin Neurosci 2018 Nov 28
- CONCLUSIONS: The results of this study suggest that amantadine may be effective as an augmentative agent in the treatment of moderate-to-severe OCD. This article is protected by copyright. All rights reserved.
- Dose-dependent neurorestorative effects of amantadine after cortical impact injury. [Journal Article]
- NLNeurosci Lett 2018 Nov 22; 694:69-73
- Numerous pharmacotherapies have been evaluated after experimental traumatic brain injury (TBI). While amantadine (AMT) has shown potential for clinical efficacy, the few studies on its effectiveness ...
Numerous pharmacotherapies have been evaluated after experimental traumatic brain injury (TBI). While amantadine (AMT) has shown potential for clinical efficacy, the few studies on its effectiveness have been mixed. It is possible that suboptimal dosing, due to the evaluation of only one dose, may be causing the discrepancies in outcomes. Hence, the goal of the current study was to conduct a dose response of AMT after TBI to determine an optimal behavioral benefit. Anesthetized adult male rats received either a cortical impact of moderate severity or sham injury and then were randomly assigned to receive once daily intraperitoneally injections of AMT (10, 20, or 40 mg/kg) or saline vehicle (VEH, 1 mL/kg) commencing 24 h after injury for 19 days. Motor and cognitive function were assessed on post-operative days 1-5 and 14-19, respectively. There were no statistical differences among the sham groups treated with AMT or VEH so the data were pooled. AMT (20 mg/kg) facilitated beam-balance recovery and spatial learning relative to VEH-treated controls (p < 0.05). No other doses of AMT were effective. These results indicate that dosing should be carefully considered when assessing the effects of pharmacotherapies after TBI so that potential benefits are not inadvertently missed.
- Spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer. [Journal Article]
- FSFuture Sci OA 2018; 4(10):FSO345
- CONCLUSIONS: Increases in SSAT-1 contents in tumor tissue could be of value in targeting cancers with high SSAT-1 expression for confirmation/quantification. The high levels of acetylated amantadine could be used as a simple and useful screening test for the presence of cancer.
- Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients. [Journal Article]
- EOExpert Opin Pharmacother 2018 Nov 09; :1-12
- Levodopa-induced dyskinesias (LID) appears in more than 50% of Parkinson's disease patients after 5 years of treatment and clinicians always have to ensure that there is a balance between the benefic...
Levodopa-induced dyskinesias (LID) appears in more than 50% of Parkinson's disease patients after 5 years of treatment and clinicians always have to ensure that there is a balance between the beneficial effect of the treatment and the potential complications. Areas covered: In this review, the authors discuss the treatment of LID. Treatment can be divided into strategies for preventing their occurrence, modification of dopaminergic therapy, and providing more continuous dopaminergic stimulation as well as the use of nondopaminergic drugs. Expert opinion: Amantadine is currently considered the most effective drug for the treatment of LID. Several compounds developed to target adenosine, adrenergic, glutamatergic, and serotonergic receptors have shown to significantly decrease dyskinesias in animal models. However, despite promising preclinical results, translation to clinical practice remains challenging and majority of these compounds failed to decrease LID in randomized controlled trials with moderate-to-advanced parkinsonian patients. Despite promising results with nondopaminergic drugs, treatment of dyskinesias is still challenging and largely due to their side effects. Future research should focus on developing treatments that can provide continuous dopaminergic delivery throughout the day in a noninvasive manner. Studies on the impact of the early administration of long-acting formulations of levo-3,4-dihydroxy-phenylalanine on dyskinesias are also necessary.
- Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study. [Journal Article]
- NeurNeurology 2018 Dec 11; 91(24):e2238-e2243
- CONCLUSIONS: Levodopa-induced dyskinesia affected 30% of the patients with PD in our cohort. Mayo neurologists favoring levodopa dosage optimization treated most patients. Dyskinesia was severe in 3.2% of all levodopa-treated patients with PD (10.7% of all patients with dyskinesia) with marked improvement among those treated with deep brain stimulation.
- Osmolex ER--another extended-release amantadine for Parkinson's disease. [Review]
- MLMed Lett Drugs Ther 2018 Sep 10; 60(1555):148-150
New Search Next
- Amantadine-induced livedo reticularis in a child treated off label for neurobehavioral disorders. [Journal Article]
- CCutis 2018; 102(3):E8-E9
- We report the case of an 8-year-old boy who was taking amantadine off label for multiple childhood neurobehavioral disorders and subsequently developed livedo reticularis. Although this side effect i...
We report the case of an 8-year-old boy who was taking amantadine off label for multiple childhood neurobehavioral disorders and subsequently developed livedo reticularis. Although this side effect is well-described in adult patients taking amantadine for Parkinson disease, it is now being seen in children as the off-label use of amantadine is expanded to this population.